01:50 PM EDT, 10/08/2025 (MT Newswires) -- Kits Eyecare ( KTYCF ) is expected to report its third-quarter results early next month.

The company pre-released its third-quarter revenue and EBITDA figures -- revenue came-in at $52.4 million, up 25%, and in-line with Stifel expectations and consensus estimates of $53 million. EBITDA margin came in at 5.2%, at the low-end of company guidance of 5%-7% and slightly lower than Stifel's expectations of 6.2% and consensus of 6%.

KITS' shares are near all-time highs as investors are rewarding management's execution, but given Q3/25 results are at the low-end of guidance, shares may take a breather, said analyst Martin Landry.

KITS is Landry's preferred small cap idea, and is rated Buy, with a $22 price target.

Price: 16.80, Change: -0.02, Percent Change: -0.12